SUPARTZ FX
Seikagaku Corp. · Decision date Jan 24, 2001
What did the FDA approve?
FDA database entry P980044 records an approval decision dated January 24, 2001, for SUPARTZ FX from Seikagaku Corp. The decision statement identifies the device as the SUPARTZ(TM) Dispo and states its indication: treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen.
The entry lists the device category as acid, hyaluronic, intraarticular, the product code as MOZ, and the specialty as orthopedic. The statement reports the approved indication but does not provide independent evidence of safety or clinical effectiveness. No supplement type or supplement reason is recorded, so the entry does not indicate whether this decision modified a prior submission.
FDA approval order statement
APPROVAL FOR THE SUPARTZ(TM) DISPO. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Jan 24, 2001
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980044
- Regulatory pathway
- Premarket approval application
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- Decision code
- APPR
- Decision date
- Jan 24, 2001
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Seikagaku Corp.
- Product code
- MOZ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P980044 received
Application receipt date recorded by FDA.
P980044 · FDA decision
APPR
P980044/S067 · Related supplement
SUPARTZ FX
Timeline entries are records held by MedtechLedger for P980044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
GEL-ONEP080020 | Seikagaku Corp. | PMA approval | Mar 22, 2011 | FDA |
| Ferring Pharmaceuticals, Inc. | PMA approval | Dec 3, 2004 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Seikagaku Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005
Sources and methodology
- Original FDA record: P980044
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


